Introduction
Most of the energy needed by human cells is provided by mitochondria in the form of ATP through oxidative phosphorylation [1] . The final stages of this process are catalyzed by an F 1 F O -type ATP synthase located in the inner mitochondrial membrane. This enzyme, also called complex V, utilizes the energy of an electrochemical proton gradient across the inner membrane to catalyze the synthesis of ATP from ADP and inorganic phosphate. This gradient is established during oxygen reduction by a series of four respiratory complexes (I-IV) embedded in the mitochondrial inner membrane.
The mitochondrial ATP synthase is a multi-subunit complex, with a molecular mass of approximately 550,000Da. It has historically been described in terms of a hydrophobic domain (F O ) containing a proton channel and a hydrophilic ATPase (F 1 ) bearing the adenine nucleotide processing sites [2] [3] [4] [5] . Strong evidence supports a mechanism in which H + translocation from the intermembrane space to the matrix through F O is coupled to the rotation of a subcomplex of the enzyme (the rotor) which in turn induces conformational changes in the F 1 that favor the synthesis of ATP and its release from the enzyme. The biogenesis of the mitochondrial ATP synthase is a sophisticated process, which depends on the coordinated expression of the nuclear and mitochondrial genomes, except in a few species, e.g. green algae, in which the whole enzyme is of nuclear origin [6] . In addition, a number of 'assembly factors' not belonging to the final enzyme performs specific actions in the synthesis, transport toward the inner membrane, and finally oligomerization of the individual ATP synthase subunits.
This review focuses on human mitochondrial diseases associated with primary deficiencies in the ATP synthase. A number of epidemiological studies within the last decade have clearly demonstrated that mitochondrial disorders are far more common than previously appreciated [7, 8] . In particular, ATP synthase defects may be underdiagnosed in clinical practice, as they are often not considered in the diagnostic approach in favor of more common conditions (e.g. asphyxia, heart failure) [9] . Nevertheless, pronounced defects of the ATP synthase of either nuclear or mitochondrial genetic origin result in highly deleterious disorders of the neuromuscular system that manifest primarily in children, very often shortly after birth [10] . To date, no causal treatment (i.e. aiming to reverse the causal factor) exists for any of these diseases. The underlying pathogenic mechanisms are certainly more complex than a mere decrease in cell energy provision. Secondary effects, such as increased production of free oxygen radicals (ROS), a decrease in the intermediary metabolism, metabolic acidosis and probably further as yet unrecognized dysfunctions, are likely to contribute to the pathogenesis of these diseases.
Various model systems have been designed to help elucidate the molecular mechanisms of ATP synthase-based diseases and the search for therapeutic solutions. Among these are transmitochondrial cytoplasmic-hybrid (cybrid) cell lines [11, 12] , and unicellular organisms (bacteria and yeast) easily tractable to genetic manipulations and biochemical analysis of the ATP synthase [13, 14] . The final section of this review highlights several ways in which yeast is being utilized for the development of strategies to treat ATP synthase deficiencies. There is every reason to believe that with minor modifications these general methods can be adapted to therapeutic screens for mitochondrial disorders that originate from genetic lesions in other proteins of the respiratory pathway.
The F 1 F O -ATP synthase

Subunit composition and topology
The overall structure and energy transduction mechanism of the ATP synthase are well conserved from bacteria to human. The simplest form of the enzyme, found in bacteria, is composed of eight different subunits with the stoichiometry α 3 β 3 γ 1 δ 1 ɛ 1 a 1 b 2 c 10-15 [3, 15, 16] . The a, b, and c subunits form the F O component, while the α, β, γ, δ, and ɛ subunits constitute the F 1 part (Fig. 1A and Table 1 ). The catalytic sites are located in the α 3 β 3 domain, one in each β subunit. This domain is connected to the membrane by the so-called central (γɛ) and The enzyme of E. coli, with a subunit stoichiometry of α 3 β 3 γδɛab 2 c 10-12 , is organized in four subdomains, i.e. the catalytic headpiece (α 3 β 3 ), the central rotor stalk (γɛ), the stator stalk (b 2 δ), and the proton channel (ac [10] [11] [12] ). (B) In human mitochondria, the central stalk (γδɛ) contains the additional subunit ɛ. The stator stalk is composed of one subunit b, subunits d, F6, f and OSCP. Subunit c is present in 10 copies. Subunits e and g mediate enzyme dimerization.
peripheral (δb 2 ) stalks. A ring of 10-15 subunits c and the subunit a constitute an integral membrane proton channel (Fig. 2) .
The mitochondrial ATP synthase differs from the bacterial enzyme in that a number of additional polypeptides contribute to its structure, regulation and supramolecular organization (Fig. 1B and Table 1 ). While there is only one subunit b in the mitochondrial enzyme, three proteins (d, F 6 , f) are believed to perform the function of the second bacterial subunit b [17] [18] [19] . The mitochondrial ATP synthase harbors a third central stalk subunit (ɛ) arranged like a clip around subunits γ and δ [20] . The subunit A6L, an integral membrane protein unique to the mitochondrial ATP synthase, is presumed to provide a physical link between the proton channel and the stator [21] . Two subunits (e, g) are involved in the supramolecular organization of mitochondrial ATP synthases [22] . Indeed, the enzyme forms ribbons of homodimers presumed to be important for the proper ultrastructural organization of the mitochondrial inner membrane [23] [24] [25] . Finally, regulatory polypeptides (IF1 in mammals; Inh1p, Stf1p, and Stf2p in yeast) have been shown to inhibit the ATP hydrolysis activity of F 1 under certain conditions [26, 27] .
The subunit nomenclature is rather complex and confusing. For example, the mitochondrial homologs of the bacterial ɛ and δ subunits are called δ and OSCP, respectively. Moreover, there are a number of differences in the designation of the subunits between yeast and mammals. To avoid misunderstandings, see the table summarizing the subunit nomenclature in Escherichia coli, Saccharomyces cerevisiae and Homo sapiens (Table 1) .
Energy transduction mechanism
The driving force for ATP synthesis derives from the translocation of protons across the inner membrane through the F O component of the enzyme. This translocation is mediated by the close arrangement of subunit a with the c subunits (Fig. 2) . The flow of protons through the F O results in the rotation of the c-ring together with the central stalk [2] [3] [4] [5] . As a result of this rotation, the three catalytic sites of F 1 sequentially transit through three states that favor the binding of ADP and P i , the synthesis of ATP and its release from the enzyme, respectively. While the crystal structure of F 1 [20, 28] and video microscopy experiments using engineered F 1 [29] provide strong support for this rotary mechanism, the detailed structure of the proton channel remains largely unknown.
However, studies in E. coli have revealed key residues for proton transport and/or rotation of the c-ring, among which are an acidic residue (D61 in E. coli, E59 in H. sapiens) in the second transmembrane helix of subunit c (c-TMH2) and a basic residue in a-TMH4 (R210 in E. coli, R159 in H. sapiens) [30] . These two residues would be in close proximity to one another near the middle of the lipid bilayer at the interface of subunits c and a (Fig. 2) . The c-D61 residues facing the lipid core are supposedly always protonated, whereas those facing subunit a can be deprotonated and charged. According to Vik et al. [31] , two half proton channels within subunit a allow the c-D61 residues at the subunits c/a interface to be successively deprotonated and reprotonated (Fig. 2A) . The binding of a proton from the periplasm by the ionized c-D61 is supposed to disrupt its electrostatic interaction with a-R210 and at the same time the proton of the neighboring c-D61 would be released and excreted into the cytosol. The newly deprotonated aspartate could then interact with a-R210 leading to a one step movement of the ring [31] . A variant of this model based on pH-induced structural changes of the c protomer in organic solvents has been proposed [15] . In this model, deprotonation of c-D61 and release of the proton trigger a 140°rotation of c-TMH2 with concomitant motion of the ring. While most of the mitochondrial proteins are encoded in the nucleus, few subunits of the energy transduction complexes are encoded by the mitochondrial genome. Two ATP synthase subunits in H. sapiens (a, A6L) [32] and three in yeast (6, 8, 9) [33] [34] [35] are encoded by the mtDNA. The expression of the respiratory genes involves a number of transcriptional factors, exclusively nuclear-encoded, that act either on the mtDNA or in the nucleus [36] . There is no evidence for gene-specific regulation of transcription in both human and yeast mitochondria. The factors governing nuclear gene expression can be divided into (i) transcription factors that bind respiratory promoters, among which are the nuclear respiratory factors NRF-1 and NRF-2, and (ii) co-activators, e.g. of the PGC family, that do not bind DNA but rather dock with DNA-bound transcription factors and facilitate chromatin remodeling [36] .
Interestingly, a specific transcriptional control on subunit c of the ATP synthase was shown to regulate the abundance of the whole enzyme in certain human tissues, such as brown adipose tissue (BAT) [37] . In this tissue, upon cold acclimation, the ATP synthase content is reduced by 10-fold whereas the mitochondrial respiratory chain enzymes are still highly abundant. The transmembrane proton gradient is then preferentially converted into heat instead of ATP through the activity of the brown adipose tissue-specific uncoupling protein UCP1. There are three isoforms of the human subunit c (P1-P3), which differ only in their targeting sequences. The transcriptional regulation of the isoform P1 level proved to be crucial for defining the amount of ATP synthase in brown adipose tissue [37] . A correlation between the levels of P1-c mRNA and ATP synthase has been observed for a number of other tissues, e.g. liver and heart [38] . This implies that the transcriptional regulation of subunit c might be a general mechanism for defining the amount of the ATP synthase in human cells in response to various stimuli.
Translational control and mRNA localization
In the mitochondria of S. cerevisiae there are gene-specific translational activators bound to the inner membrane that mediate productive interactions between mitochondrial mRNAs and ribosomes at the surface of the membrane, suggesting a co-translational insertion of the mtDNA-encoded proteins [39, 40] . These factors may regulate the rate of protein synthesis in mitochondria and/or localize translation to sites where the mitochondrial gene products can be efficiently assembled. Regarding the ATP synthase, Atp22p was recently reported to 
specifically activate the translation of Atp6p [41] . However, to date there is no evidence for the existence of gene-specific translational activators in human mitochondria. It remains possible, however, that the mtDNAencoded proteins are synthesized in the vicinity of the inner mitochondrial membrane also in human cells.
While it is widely accepted that the nuclear-encoded mitochondrial proteins are synthesized on free ribosomes in the cytosol before they are imported into mitochondria [42] , there is recent evidence that a subclass of proteins is translated on mitochondria-associated ribosomes [43] . Regarding the ATP synthase, the mRNAs of a number of subunits (α, β, γ in yeast [44] ; β in H. sapiens [45] ) were found to be preferentially, if not exclusively, located on the mitochondrial surface. The subcellular addressing of these mRNAs requires cis-acting elements located in their 3′UTRs that are apparently required for a proper interaction with the translational machinery [46] . The binding of putative regulatory proteins to the 3′UTR is thought to be responsible for the translation masking of β-F 1 mRNA observed during liver development and in kidney cells [47, 48] . Thus, in addition to the transcriptional regulation of the P1 subunit c gene, specific translational controls on other ATP synthase subunits may also play a role in determining the abundance of this enzyme in human cells.
Assembly
The current hypothesis regarding the assembly of the ATP synthase is mainly based on the isolation and analysis of assembly-deficient yeast mutants and on data on its subunit topology [6, 49] . It is thought that, after synthesis on mitochondrial ribosomes, subunit 9 (or Atp9p) oligomerizes to form a 10 subunits ring to which the F 1 sector is subsequently attached. The c-F 1 pre-complex is thought to be further completed by the addition of Atp8p, followed by Atp4p, the other components of the stator arm, and finally Atp6p (Fig. 3 ). The addition of Atp6p at a late stage of the assembly may prevent the formation of partially assembled enzymes that could dissipate the mitochondrial membrane potential through F O -mediated proton leaks [50] . However, the possibility of an alternative pathway [51] cannot be ruled out, in which the assembly of the F O -part may proceed through to the point where subunit 6 and the stator stalk join the c-ring, followed by the integration of the F 1 -subcomplex.
Biogenesis of the F 1 requires the mitochondrial chaperone Hsp60p and at least three factors in yeast: Atp11p, Atp12p [52] and Fmc1p [53] . Atp11p and Atp12p, which are conserved in H. sapiens [54] , function as molecular chaperones that probably stabilize unassembled α-F 1 and β-F 1 subunits by shielding their hydrophobic surfaces [55, 56] . In the absence of either Atp11p or Atp12p, the α-F 1 and β-F 1 aggregate within large inclusion bodies in the mitochondrial matrix [52, 57] .
The assembly of the F O also requires at least three proteins in yeast: Atp10p [58] , Atp23p [58] [59] [60] and Atp25p [61] . The latter is required for the expression of Atp9p, and was proposed to be involved in the formation of the subunit 9 ring [61] . No human homolog has been described so far. The two other factors are required for the incorporation of Atp6p into the ATP synthase complex. The Atp6p subunit is synthesized with an N-terminal pre-sequence of 10 amino acid residues [62] that is cleaved by Atp23p, a membrane-bound metallo-protease with the characteristic HXXHH motif [59, 60, 63] . Interestingly, mutations in this motif prevent the maturation of the subunit 6 precursor, but not the assembly of the ATP synthase. Thus, in addition to its processing activity, Atp23p must provide another important function in the assembly of the F O . In H. sapiens, there is a clear homolog of Atp23p while the human subunit a lacks an Nterminal extension [59, 63] . Therefore, the human ATP23 might either have retained only a chaperone function towards subunit a, or it might cleave other as yet unidentified substrates [59, 63] , or it might fulfill both tasks as described for several other mitochondrial proteases. However, there is no direct evidence for its involvement in the assembly of the human ATP synthase.
Disorders related to primary defects in the mitochondrial ATP synthase
Patients suffering from disorders related to primary defects in the F 1 F O -ATP synthase present with a wide variety of symptoms. Due to the dual genetic origin of mitochondria, underlying mutations are located either in nuclear or mitochondrial DNA. While the mitochondrial mutations have been found in the two mitochondrially-encoded subunits of the enzyme (a and A6L), only one of the nuclear mutations has been identified so far (Table 2) . Fig. 3 . Assembly of the yeast mitochondrial ATP synthase. The assembly proceeds in a sequential order and is assisted by specific chaperones (indicated above arrows). Initially, the F 1 -headpiece, the ring of subunits 9, and the central stalk, are pre-assembled and then attached to one another. Next, subunit 8 and the peripheral stalk are added to the pre-complex. Subunit 6 is incorporated as a last step to render the enzyme functional. ATP synthase monomers can be further assembled into dimers involving subunits e and g.
ATP synthase-based diseases of nuclear genetic origin
The first defect in the ATP synthase with a confirmed nuclear origin was reported by Houstek and colleagues in the case of a child with severe lactic acidosis, cardiomyopathy and hepatomegaly, who died 2 days after birth [64] . The ATP synthase content was decreased by 70-80% in all analyzed patient's tissues, whereas the respiratory chain complexes were essentially unaffected. The structural genes of the ATP synthase did not show any mutation or expression deficit. All these findings indicated that the low content of the enzyme was due to a mutation in some factor specifically involved in ATP synthase assembly. Since then, several similar cases have been reported [9] . Unfortunately, the nuclear mutations causing the above-mentioned diseases remain mostly unknown. All these patients have been screened for mutations or altered levels of expression in the conserved assembly factors ATP11 and ATP12, initially described in yeast. Only in one case was a homozygous point mutation found in the ATP12 gene [65] . This implies for the other cases the etiological involvement of as yet unidentified ATP synthase assembly factors. Table 2 ) have been associated with a group of maternally inherited, early onset neurodegenerative syndromes [10, 66, 67] : NARP, MILS and FBSN. The name of the NARP syndrome is derived from its main clinical manifestations, Neuropathy, Ataxia, and Retinitis Pigmentosa [68] . MILS is the maternally inherited form [69] of the Leigh syndrome (LS), a fatal encephalopathy of infancy [70] , that has been associated with mutations in nuclear-encoded subunits of complex I and IV [71] [72] [73] , as well as pyruvate dehydrogenase [74] . A similar, but less progressive syndrome is the 'Familial Bilateral Striatal Necrosis' (FBSN) [75] .
3.2.1.1. Mutations at position nt8993. The most common and best studied of the pathogenic ATP6 mutations is T8993G. This mutation leads to replacement of a highly conserved leucine by arginine at position 156 of subunit a [68] (Fig. 5) . In patient tissues, the thousands of molecules of mtDNA per cell consist of a mixture of both mutated and wild-type mtDNA, a situation that is referred to as heteroplasmy. Different mutation loads result in distinct clinical presentations. A level of approximately 70% of mutated mtDNA has to be exceeded in order to provoke clinical symptoms. Patients with a mutation load within the range of 70-90% mainly develop the NARP syndrome, while a level of mutated mtDNA higher than 90% usually results in the manifestation of MILS [76] .
Analysis of patient's fibroblasts and cybrids has shown that high loads of T8993G result in a 50-90% decrease in the rate of ATP synthesis [77, 78] . Initially it was proposed that the decrease in ATP production could be at least in part due to defects in assembly and/or stability of the ATP synthase [12, 77, 79] . However, a recent thorough study on ATP synthase assembly in cultured human cells homoplasmic for T8993G failed to show any assembly defect. This would suggest that this mutation may rather cause a local disruption of the enzyme's proton channel [80] . This view is supported by the topological model introduced in section II.2, in which the leucine 156 (L207 in E. coli) is in close proximity to other residues critical for proton translocation, both in subunit a and c (Figs. 2 and 4) . Still, the impact of the T8993G mutation at the molecular level remains controversial. Some have claimed that the proton flow through the F O is not tightly coupled to ATP synthesis in the mutated enzyme [67] , while others have proposed a blockage of the proton channel [78] . The reasons for the different outcomes of the studies on the influence of T8993G on the assembly of the ATP synthase are still unknown. Special features regarding the type of sample analyzed (biopsies of patient's tissues, cultures of fibroblasts and cybrids) might be responsible for the apparent discrepancy.
ATP hydrolysis activity assays on disrupted mitochondrial membranes indicate that the T8993G mutation does not affect the reverse functioning of the ATP synthase [69, 77, 81, 82] . Similar experiments carried out on a yeast model of the T8993G mutation confirmed these results [13] . However, the further analysis of ATP hydrolysis sustained proton pumping (assayed on intact mitochondria) in this model revealed a clear alteration in the mitochondrial membrane potential. So far, only one study has addressed this in human NARP cells, and failed to detect significant differences [83] . This might however be attributed to the use of inverted mitochondrial membranes instead of intact mitochondria, which in this case were derived from patients' platelets with a 15-90% heteroplasmy. Moreover, the latter implies the presence of wild-type ATP synthase complexes in the analyzed submitochondrial particles, which might sufficiently account for the observed proton pumping activity. Although yeast and human ATP synthases may be differently affected by the T8993G mutation, the results obtained in those studies imply the need for further analyses, carried out in more suitable conditions, in order to draw firm conclusions about the influence of mutations on the reverse functioning of the human ATP synthase. a Two basepair deletion in the ATP6 stop codon. b Nonsense mutation in codon 5. Fig. 4 . Positions of the pathogenic mutations in ATP6. 3D-folding model of the E. coli subunit a (the last four transmembrane segments) according to Rastogi and Gavin [15] (Protein Data Bank entry 1C17). The catalytic arginine a-R210 is represented in blue. The E. coli residues corresponding to the mutated ones in the human subunit a in NARP, MILS and FBSN (see Fig. 5 ) are represented in red. The corresponding mutations and residue exchanges in the human subunit a are indicated. Another mutation at position 8993 -a T to C transition, converting Leu-156 to Pro -also accounts for cases of NARP syndrome and MILS, but usually results in a milder clinical presentation than T8993G [84, 85] . Consistent with this, the rate of ATP synthesis was found to be only slightly diminished in patients' fibroblasts or cybrids containing high loads of T8993C (up to 100%), in apparent contrast to the T8993G cells [86] . However, in a recent study of several children with a 95% load of this mutation, significant (50%) decreases in activity and impaired assembly/stability of complex V have been observed in muscle biopsies [87] . Thus, a direct impact of ATP undersupply cannot be ruled out, even though it has been suggested that cellular oxidative damage due to an increased level of reactive oxygen species (ROS) may be the main pathogenic factor in T8993C patients [88] . T9176G/T9176C. These mutations result in a replacement of the conserved leucine 217 by either arginine (T9176G) or proline (T9176C) [75, 89, 90] . A high mutation load (95%) of T9176G in patient's fibroblast was associated with a massive reduction of the ATP synthesis rate ( b 20% of control) [89] . Modeling this mutation in E. coli confirmed this observation, as neither significant ATP synthesis, hydrolysis nor proton pumping activity was detectable [14] . The T to C transition at this position results in clinical symptoms only at very high levels of heteroplasmy and usually causes a milder phenotype [75, 91, 92] . In addition, the rate of ATP production was basically unaffected in the patients described [75] . However, there are also reports of fulminant progression of Leigh syndrome in patients harboring the T9176C mutation [93, 94] . Future studies will be needed to decipher the molecular function of Leu217. T8851C. The T8851C mutation, which results in the replacement of the conserved tryptophan 109 in the second transmembrane helix by arginine, has so far been reported only in a single case [95] . No thorough analysis of the impact of this mutation on the ATP synthase has yet been carried out T9185C/T9191C. Two novel missense mutations in the ATP6 gene, T9185C and T9191C, have recently been described [96] . These mutations cause the substitution of either of the conserved leucine residues in the fifth transmembrane helix by proline at positions 220 and 222, respectively. In spite of a high mutation load, patients harboring the T9185C mutation present with a relatively mild form of Leigh syndrome [96, 97] . The analysis of patients' lymphoblast mitochondria revealed that the ATP synthesis rate is not affected, while the ATP hydrolysis sustained proton pumping activity is decreased by 30% [97] . In contrast, the T9191C mutation was associated with a distinctly more severe clinical phenotype with a reduced respiratory rate and more pronounced impairment of the ATP hydrolysis activity [96] . ΔTA9205. One mutation of a different kind is the two-nucleotide micro-deletion (ΔTA9205) within the stop codon of the ATP6 gene that modifies the processing site within the tri-cistronic ATP8-ATP6-COX3 transcript [98] . It is a very rare mutation, so far reported in only two cases [99, 100] . Even though both cases were nearly homoplasmic (N 98%), their clinical manifestations were very different. In line with that, a detailed molecular and biochemical analysis of cultured fibroblasts from both patients revealed major differences [100] [101] [102] . In the more severely affected patient several alterations were observed: a reduction of subunit a biosynthesis; an accumulation of incompletely assembled ATP synthase; a 3-fold decrease in mitochondrial ATP production; a reduction in COX activity by around 85%. These results have been attributed to the impaired maturation of the ATP8-ATP6-COX3 transcript [100] . The other patient, however, merely exhibited a reduction in the steady state level of the ATPase 8-and 6-encoding bi-cistronic mRNA, while biogenesis and function of the ATP synthase appeared unaffected [101, 102] . To date, there is no explanation for the pronounced discrepancy between these two patients. One can only speculate that the phenotypic differences may be due to further mutations within the mtDNA, or to the presence of a compensatory mechanism in the less severely affected patient, which could potentially be mediated by an unknown factor involved in posttranscriptional processing and translation of the ATP6 mRNA.
Finally, one further mutation in the ATP6 gene has been ascribed to a different clinical presentation. The T9101C mutation has been reported in a patient suffering from Leber's hereditary optic neuroretinopathy (LHON) [103] , a maternally inherited eye disease resulting in bilateral optic atrophy in young adults [104] . In this case a reduction in the efficiency of oxidative phosphorylation, attributed to a proton leakage, has been observed [103, 105] . It is, however, surprising that the replacement of isoleucine 192 by threonine in this weakly conserved region of subunit a results in such a bioenergetic alteration, as threonine is the prevailing residue at this position for many other species, including cattle, mice and rats (Fig. 5 ).
A pathogenic mutation of the mitochondrial ATP8 gene
Recently, a homoplasmic nonsense mutation in the mitochondrial ATP8 gene has been detected in a 16-year-old patient with apical hypertrophic cardiomyopathy and neuropathy [106] . The mutation is located in the overlapping region of ATP6 and ATP8 (nucleotides 8527-8572). It results in a silent change of the initiator methionine codon of ATP6, and induces a premature stop codon in ATP8, leading to a truncated A6L protein that lacks the last 14 amino acids. The analysis of patient's fibroblasts, muscle tissue and derived cybrids showed a decreased mitochondrial ATP synthesis rate, a lack of fully assembled complex V and an accumulation of ATP synthase subcomplexes [106] . These results reveal the importance of the C-terminal region of the ATP8 gene product (A6L) for the assembly/stability of the ATP synthase.
Secondary pathogenic effects
The phenotypic presentations observed in several of the previously described ATP synthase deficiencies cannot be accounted for simply by a lack of ATP provision. Attention has therefore turned to the quest for secondary effects that could be involved in the pathogenic mechanisms.
A well-documented example is the investigation of the role of reactive oxygen species (ROS) in mitochondrial diseases. Under normal physiological conditions, 2-4% of the oxygen consumed by mitochondria are converted to superoxide anion instead of water due to unproductive electron transfer within complexes I and III [107] [108] [109] [110] . When the respiratory chain is slowed down, more electrons are diverted from their normal pathway, resulting in an elevated ROS production. Such a situation can be found in the case of ATP synthase deficiencies, as in tightly coupled mitochondria a limited rate of ATP synthesis results in a high membrane potential, and hence in a slowing down of the electron transfer rate along the respiratory chain [111] .
A study of cybrid cells containing various proportions of T8993G revealed the importance of cellular oxidative damage in NARP/MILS, as evidenced by the ability of various antioxidant agents, which promote ROS scavenging, to significantly improve mitochondrial respiration and ATP synthesis in the T8993G cells [112] . Other reports using cultures of fibroblasts from patients with a high level of T8993G (N 90%) appear to show a dramatic increase in superoxide dismutase activity (SOD), mediated by the actin-Nrf2 signaling pathway, and in apoptotic cell death [113, 114] . Both effects were successfully rescued by perfluoro-tri-phenyl, an antioxidant spin-trap molecule. Thus, in addition to energy deprivation, patients with ATP synthase deficiencies may suffer from a chronic up-regulation of ROS that may override their antioxidant defense capacity [115] .
In an attempt to gain a more global view of the cellular consequences of ATP synthase dysfunctions, microarray analyses have been performed to evaluate the associated nuclear transcriptional response [116] [117] [118] . The results of such studies may direct our attention to other so far unrelated cellular pathways, as exemplified by an up-regulation of genes related to the unfolded protein response (UPR) and to the cell cycle in a recent report using cybrid cells harboring a T8993G mutation [116] .
Considering mitochondria beyond their bioenergetic function might be crucial for a complete understanding of pathogenic pathways at a molecular level. In recent years mitochondria have come to be seen as highly dynamic organelles that continuously move, fuse and divide [119] . Furthermore, it has been established that mitochondrial membrane dynamics can modulate mitochondrial and cellular functions [120] . In humans, mutations of genes encoding components of the mitochondrial fusion/fission machineries are associated with various neuropathies [121] [122] [123] . In addition, mitochondrial dysfunction provokes changes in mitochondrial morphology as exemplified in several models of mitochondrial pathologies [124] , indicating a close relationship between membrane dynamics and energy metabolism. Furthermore, oligomerization of the ATP synthase apparently plays an important role in the structural organization of the inner mitochondrial membrane in cristae [23, 25, 125, 126] . Therefore, changes in the morphology and ultrastructure of mitochondria may also contribute to the underlying pathogenic mechanisms of ATPase-based diseases.
Recently, several reports have revealed that the F 1 F O -ATP synthase is also present in the plasma membrane in various cell types. At this location it is thought to play a role in regulating angiogenesis and as a receptor for apolipoprotein A-I [127] [128] [129] [130] [131] [132] . It is possible that a concomitant impairment of an ectopic function of the ATP synthase is involved in the pathogenesis of ATP synthase-based diseases.
Current and prospective therapeutic strategies for ATP synthase deficiencies
In spite of the considerable progress in our understanding of the molecular mechanisms underlying mitochondrial diseases, the available therapeutic approaches are still extremely limited and there is no specific treatment for ATP synthase deficiencies.
Pharmacological approaches
The administration of drugs in ATP synthase-based diseases is aimed at treating the symptoms (e.g. seizure control by anticonvulsants), eliminating noxious metabolites and supplying with oxygen radical scavengers (reviewed in [133, 134] ). The specific targeting of drugs, especially antioxidants, to mitochondria has recently received considerable attention [135] [136] [137] [138] . The role of all these supportive therapeutic strategies has however not been demonstrated as there is no clear evidence supporting the use of any of these treatments [139, 140] .
Genetic-based therapeutic strategies
The current inadequacy of treatment for patients with mitochondrial disorders highlights the need to develop gene therapy strategies. In addition to the many unsolved challenges for gene therapy in general, the genetic modification of mtDNA encounters further difficulties, such as the presence of multiple mtDNA copies per cell, heteroplasmy and the complexity of manipulating the mitochondrial genome in living cells. Nevertheless, several experimental strategies have been developed [133, 134, [141] [142] [143] [144] [145] , of which two will be discussed below.
Complementation through allotopic expression
One possible gene therapy for disorders resulting from mutations in the mtDNA exploits the allotopic expression of mtDNA-encoded polypeptides. In this approach, initially established in yeast [146, 147] , a protein normally encoded by the mtDNA is synthesized in the cytosol from an alternative nuclear version of its gene fused to a mitochondrial targeting sequence (MTS).
A critical element in this approach is the efficient mitochondrial import of the allotopically expressed protein, and its assembly in the dedicated protein complex. In order to achieve this, it appears essential to select a suitable MTS, as the proteins encoded by the mtDNA are very hydrophobic, and this is thought to limit their import efficiency.
The allotopic expression strategy has been used in an attempt to remedy the ATP synthase deficiency resulting from the T8993G mutation. Initial attempts have been made by fusing typical human MTSs (e.g. those of COX8 and isoform P1 of ATP synthase subunit c) N-terminally to the human subunit a. These constructs were found to be transported into mitochondria with a rather low efficiency, and only a modest recovery of the NARP cells was observed, if any at all [148] . Another experiment was conducted with the Atp6 subunit of Chlamydomonas reinhardtii. In this organism the Atp6 subunit is naturally encoded in the nucleus with a very long MTS (107 amino acids) that is believed to facilitate its transport into mitochondria [149] . In this case too, a very weak complementation was reported [150] . Furthermore, the allotopic expression of the Chinese hamster ATPase6 in wild-type Chinese Hamster Ovary (CHO) and T8993G cybrid cells was reported. In this study, an oligomycin resistance mutation was included in the nuclear version of ATPase6 gene, which apparently gave the engineered cells a 1000-fold increase in oligomycin resistance [151] . A more recent study has cast all these results into doubt, pointing out that essential controls were missing and that no convincing conclusion could therefore be drawn, as the observed partial complementation could be of unspecific origin [152] .
Finally, a very recent study using fibroblasts with a 95% heteroplasmy for the T8993G mutation investigated whether translation on mitochondria-associated ribosomes improves the allotopic expression of human subunit a. To this end, the authors equipped an engineered ATP6 gene with the MTS and 3′UTR of the SOD2 gene. These elements were shown to direct the SOD2 mRNA to the mitochondrial surface [153] . The translated protein was more efficiently transported into mitochondria, was able to restore the ATP synthesis defect and allowed survival in a galactose medium. However, the 3′UTR of SOD2 was not essential for complementation and no direct evidence was provided for the association of the hybrid ATP6 transcript with mitochondria.
Thus, even though promising preliminary studies raise hopes for the allotopic expression strategy, further experiments are required to settle the questions raised by the experimental data obtained so far.
Manipulation of heteroplasmy
One characteristic feature of mitochondrial diseases is the relation between the manifestation and gravity of symptoms and the cellular ratio of mutant to wild-type mitochondrial DNA [154] [155] [156] . The manipulation of this ratio appears to be a desirable therapeutic target. Several such approaches in this direction have been described in recent years [141, 144] .
One idea is to specifically inhibit the replication of mutant mitochondrial DNA through the sequence-specific binding of peptide nucleic acids (PNAs) [157] [158] [159] [160] . Another concept emerges from a recent study that has demonstrated the use of a chimeric zinc finger methylase for the sequence-specific modification of mtDNA [161] . The authors propose to use engineered zinc finger peptides (ZFPs) with a nuclease activity to specifically disrupt mutated mtDNAs [161] . A similar approach derives from the fact that certain pathogenic mutations create unique restriction sites in the mtDNA (e.g. T8993G results in a unique SmaI/XmaI site). It has been shown that targeting the corresponding restriction endonucleases to mitochondria induces the specific elimination of mutated mtDNA [162] [163] [164] . Such an approach resulted in a successful shift of heteroplasmy in muscle and brain tissues of mouse models containing specific polymorphic variants of mtDNA [165] . This strategy is however limited, as the probability of a random mutation creating a unique restriction site in the mtDNA sequence is extremely low.
These approaches could achieve the elimination of the mutated alleles, followed by the repopulation with wild-type mtDNA. This in turn could prevent the onset or alleviate the symptoms of a disease associated with heteroplasmic mtDNA mutations. It must be stressed that all of these techniques are still in an experimental phase and encounter a number of technical problems. Yet they potentially provide the basis for the development of novel and effective treatments.
5. Yeast as a model system for the study of ATP synthase-based diseases
Yeast models of ATP synthase-based diseases
Due to its ability to conduct ethanolic fermentation, baker's yeast (S. cerevisiae) can survive mutations that impair mitochondrial respiration [166] . This capacity makes it an invaluable tool in mitochondrial research, as it allows for the identification of genes required for the biogenesis and function of mitochondria [167, 168] . Hence, over the past 25years, respiratory-deficient yeast mutants have revealed hundreds of nuclear genes with mitochondrial functions [168, 169] . Many of these genes have human orthologs, of which several have been implicated in various diseases [169] , e.g. the assembly factor ATP12 concerning the F 1 F O -ATP synthase [9, 65] . Ongoing studies in yeast promise to uncover novel factors, thus providing the basis for identifying as yet unrecognized nuclear mutations, which account for ATP synthase related mitochondrial disorders.
Furthermore, S. cerevisiae proved to be a valuable model system for defining the impact of human mtDNA mutations on mitochondrial structure and function [13, 170] . Using a biolistic (biological ballistic) procedure, defined mutations can be introduced into the yeast mtDNA [169] . A homoplasmic population is easily obtained, due to the natural instability of heteroplasmy in this organism. It was long believed that deleterious mutations in the yeast mitochondrial ATP synthase genes would destabilize the mtDNA [171] . However, we have shown recently that mutations in the yeast mitochondrial ATP6 gene have only a very limited impact on mtDNA stability, even if they severely compromise the F O [13, 172] . While both in humans and in yeast the T8993G mutation drastically reduced the rate of mitochondrial ATP synthesis due to a local disruption within the ATP synthase proton channel [13, 80] , the E. coli model of this mutation showed a complete lack of assembly of subunit a [14, 173] . The dual genetic origin and the more sophisticated structure of mitochondrial ATP synthase, with at least 10 subunits not present in the bacterial enzyme, may account for the observed differences. By contrast, mutations modeled in yeast have a higher chance of mimicking mutations found in the human mitochondrial ATP synthase as the two enzymes are highly similar, not only in their structure but also in their assembly pathway. Yeast models of four other ATP6 mutations (T8993C, T9176C, T9176G and T8851C) found to be pathogenic in humans have been constructed and analyzed (Kucharczyk and di Rago, in preparation).
5.2.
Yeast-based approaches for seeking mechanisms for remedying ATP synthase deficiencies
Genetic suppressors
Yeast can also be used to uncover potential rescuing mechanisms that might enable the treatment of patients suffering from mitochondrial diseases [174] . One approach aims to discover genetic suppressors. The term suppression designates the reversal of a mutant phenotype via an additional mutation that does not restore the original genotype. The suppressor mutation can be located (i) within the same gene as the primary mutation, thus being referred to as intragenic suppression; (ii) in a different gene within the same genome, i.e. intergenic suppression; and (iii) in the case of the mitochondrial energy transduction system, it can also be intergenomic, as both the nuclear and the mitochondrial genomes encode for components of the oxidative phosphorylation complexes. Suppression can also be the result of an increased gene dosage (multicopy suppressors).
The discovery of genetic suppressors may disclose unpredictable connections between different cellular pathways. Using this approach, we have recently discovered a suppressor mechanism of special interest for mitochondrial pathologies. In our study, we used a primary mutation (Δfmc1) resulting in a major decrease (N 90%) in the ATP synthase content [53] , as observed in patients bearing nuclear mutations in ATP12 and other yet unidentified genes. A completely unexpected suppressor was Odc1p [175] , a member of the mitochondrial carrier family, which exchanges intermediates of the TCA cycle across the inner membrane [176] . Odc1p transport activity is a controlling step in the TCA cycle. A 10-fold increase in Odc1p content was found to increase ATP production through mitochondrial substrate-level phosphorylation, and to subsequently lead to derepression of the biogenesis of the respiratory chain complexes [175] . Alternative ATP synthesis via this pathway is sufficient to sustain strong respiratory growth despite of a very low content in ATP synthase. This suppressor mechanism was also found to substantially improve the respiratory capacity of the yeast NARP T8993G model (Rak and di Rago, in preparation). Thus, metabolic suppression is certainly a lead worth following to explore therapeutic solutions for mitochondrial diseases.
Pharmacological suppressors
Although yeast has been extensively used for the study of mitochondrial diseases, and several yeast models of human mitochondrial diseases are available, the pharmacological approach has so far been neglected. We consider such an approach to be very promising, as available chemical libraries comprised of tens of thousands of substances can be tested in a rather short period of time. Such a screening employing a yeast-based assay has already been successful in the selection of drugs active against mammalian prions [177] .
Using such an approach, promising molecules active on yeast models of ATP synthase deficiencies have already been isolated (E. Couplan and M. Blondel, unpublished). These drugs will be next tested on mammalian cells (fibroblasts, cybrids) that model the same diseases. Another interesting model for testing the selected drugs is a Drosophila melanogaster mutant presenting a neuromuscular disorder, which originates from sequence modifications in the ATP6 gene [178] . Yet, to our knowledge, this is the only animal model of ATP synthase deficiency available to date.
Conclusion
In spite of the recent progress in our understanding of the assembly and function of the mitochondrial F 1 F O -ATP synthase, the pathogenic mechanisms of ATP synthase disorders are not yet well understood. Furthermore, there are very few ways of treating the large number of patients suffering from these diseases. Fresh light is thrown on the molecular causes of these diseases by using alternative model systems in studying the primary and secondary effects of ATP synthase deficiencies. In the near future, the further development of novel therapeutic approaches, and of sophisticated strategies in the search for alternative therapeutic pathways, promises to improve the outlook for people suffering from these mainly fatal diseases.
